HB 75 amends Pennsylvania's Osteopathic Medical Practice Act to update the definition of "primary supervising physician" to include medical doctors (MDs) licensed by the State Board of Medicine, alongside osteopathic physicians (DOs). This change allows physician assistants to have either an MD or a DO as their primary supervising physician under a written agreement, expanding oversight options beyond current restrictions. The amendment takes effect 60 days after enactment and does not alter other provisions of the law.
HB 1127 authorizes Pennsylvania to join the Dentist and Dental Hygienist Compact, enabling dentists and dental hygienists licensed in Pennsylvania to practice in other participating states without obtaining separate licenses. The bill establishes a "Compact Privilege" that allows qualified professionals to practice across state lines while maintaining each state's regulatory authority over scope of practice and disciplinary actions. Key mechanisms include streamlined licensure pathways, shared disciplinary information between states, and protection of public health standards. This affects licensed dental professionals seeking to work in multiple compact states, particularly addressing workforce mobility and access to care.
HB 69 amends Pennsylvania's Cancer Drug Repository Program to allow unused, unopened cancer prescription drugs to be redistributed to indigent patients through approved pharmacies. The bill updates definitions (e.g., clarifying "cancer drug" includes drugs treating cancer or its side effects), requires drugs to be in original sealed packaging with unexpired dates, and mandates the State Board of Pharmacy to maintain a list of approved participating pharmacies. It also adds requirements for annual reporting and establishes procedures for restocking and dispensing drugs while maintaining safety standards. This directly affects indigent cancer patients seeking affordable medication and pharmacies participating in the program.
HB 1925 regulates how healthcare facilities, insurance companies, and Medicaid/CHIP managed care plans can use artificial intelligence. It requires the Department of Health, Insurance Department, and Department of Human Services to create rules for AI safety and transparency in these sectors. The bill imposes penalties for failing to comply with these new requirements. It directly affects providers and insurers operating in Pennsylvania's health and insurance systems.
HB 1117 amends Pennsylvania's 1929 Administrative Code to redefine the Department of Drug and Alcohol Programs' responsibilities for addressing substance use disorders. The department must now develop a comprehensive State plan coordinating prevention, treatment, research, and education across all state agencies and local communities - including health, law enforcement, education, and workforce sectors - to avoid duplication. The plan requires annual review and updates, and mandates the department to provide assistance to local governments while collaborating with medical professionals on drug use guidelines. This change formalizes existing coordination efforts under a unified framework, directly affecting state agencies and local entities managing substance use disorder services.
This Pennsylvania House Resolution designates June 23, 2026, as Dravet Syndrome Awareness Day to highlight a rare genetic form of epilepsy that affects approximately 20,000 people in the United States. The bill does not change laws or allocate funding but serves to raise public awareness about the condition, which often begins in infancy with temperature-sensitive seizures and can lead to developmental delays. By recognizing this specific date, the resolution aims to honor medical professionals and families impacted by the disease while acknowledging the importance of early diagnosis and comprehensive care.
HB 1460, the Health System Protection Act, requires health care entities (like hospitals and clinics) and certain investors (such as private equity firms) to obtain pre-approval from Pennsylvania's Department of Health and Attorney General before completing major transactions. This applies to sales of assets worth $10 million or more, ownership changes, or large financial distributions that could affect competition, costs, or access to care. The law prohibits transactions deemed "against the public interest," such as those reducing competition, raising prices, or limiting services in rural or low-income areas. Health care entities must either file a notification with a waiting period or get written approval before proceeding.
This bill establishes legal protections for music therapy by requiring anyone who identifies as a music therapist to hold a valid certification from the Certification Board for Music Therapists. It prohibits unlicensed individuals from claiming to be music therapists, using specific credentials like "MT-BC," or implying they are qualified to provide clinical music therapy services. While the law allows professionals to use music in their general work, it strictly forbids them from representing themselves as certified music therapists without the proper credential. Violations of these rules are classified as third-degree misdemeanors and are also treated as unfair trade practices under state consumer protection laws.
This bill amends Pennsylvania's Insurance Company Law to update definitions and provisions related to health insurance coverage. It clarifies how certain government health programs are defined for insurance policies, specifically regarding prescription drug coverage and continuation of coverage for employees who lose their jobs. The legislation also updates the legal definition of a hospital to include facilities operating alcoholism or drug addiction treatment programs and establishes a Long-Term Care Partnership Program to help individuals manage future long-term care costs.
HB 2427 amends Pennsylvania's Insurance Company Law to regulate how insurers cover drugs for stage four, advanced metastatic cancer. The bill prohibits insurance policies from requiring patients to fail a different medication or prove a history of failure before approving coverage for a new drug, provided the drug is FDA-approved and aligns with current clinical best practices. This legislation also repeals the previous Fair Access to Cancer Treatment Law while ensuring that all existing rules, contracts, and decisions made under that law remain in effect.
